PRQR — ProQR Therapeutics NV Share News
0.000.00%
Last trade - 00:00- $182.05m
- $68.00m
- €16.35m
Brief: ProQR Reports Q2 2022 Operating and Financial Results
Brief: Proqr Announces First Quarter 2022 Operating And Financial Results
ProQR Therapeutics NV expected to post a loss of 24 cents a share - Earnings Preview
Brief: Proqr Announces Additional Sepofarsen Illuminate Trial Analyses
Brief: ProQR Appoints John Maraganore, PhD, As Strategic Advisor To The Supervisory Board
Brief: ProQR Therapeutics NV Files For Resale Of Up To 3.7 Million Ordinary Shares By The Selling Shareholders
ProQR Therapeutics NV reports results for the quarter ended in December - Earnings Summary
Brief: ProQR Announces Fourth Quarter And Full Year 2021 Operating And Financial Results
ProQR Therapeutics NV expected to post a loss of 19 cents a share - Earnings Preview
Brief: ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
Brief: ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
Brief: ProQR Therapeutics Says May Offer And Sell Its Ordinary Shares Having Aggregate Offering Price Of Up To $75 Mln
Brief: ProQR Therapeutics Files Prospectus Related To Resale Of Up To 3.99 Mln Of Ordinary Shares By Selling Shareholders
Brief: Proqr Therapeutics NV Files For Mixed Shelf Of Up To $300 Million – SEC Filing
Brief: ProQR Therapeutics Files Prospectus Relating To Resale Of Up To 3.99 Million Ordinary Shares
Brief: ProQR Announces Third Quarter 2021 Operating And Financial Results
Editas plunges after early data from retinal disorder therapy study
Editas falls after retinal disorder therapy data; rival ProQR jumps
U.S. STOCKS ON THE MOVE-Twist Bioscience, Box, Support.com